PTEN and prostate carcinoma: Extensive in vitro and in vivo data, including those from depletion of ARID4B in the PTEN-deficient prostate cancer cell line PC3 and the prostate-specific Arid4b and Pten double knockout mouse model, demonstrated that PTEN-deficient prostate cancer depends on ARID4B.